Ebrahim Variava - Concepedia

Author

Ebrahim Variava

Also Known As

Avy Violari, B Luke, E Variava, E. Variava, Ebrahim Variava, Ebrahim Variava (403647), Jurgens Lombaard Johannes, Nadine Van Looy, Pieter Jooste, Sheleika Singh

189

Publications

5.6K

Citations

H-Index

Concepts

All Affiliations

University of the Witwatersrand Perinatal HIV Research Unit University of KwaZulu-Natal National Health Laboratory Service Kalafong Hospital

About

Ebrahim Variava is an author at University of the Witwatersrand specializing in medicine, epidemiology, and hiv.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	744
2	Public Health	5	5	248
3	Health Sciences	1	1	16
4	Nursing	1	1	76
5	Social Sciences	1	1	76

Ebrahim Variava

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis Francesca Conradie, Tatevik R. Bagdasaryan, Pauline Howell, New England Journal of Medicine	2022	507
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt, The Lancet Pulmonary TuberculosisPhase 2BTuberculosis PreventionPharmacologyTuberculosis	2015	248
High Nasopharyngeal Pneumococcal Density, Increased by Viral Coinfection, Is Associated With Invasive Pneumococcal Pneumonia Nicole Wolter, Stefano Tempia, Cheryl Cohen, The Journal of Infectious Diseases	2014	193
Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study Waasila Jassat, Caroline Mudara, Lovelyn Ozougwu, The Lancet Global Health	2021	175
Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study Waasila Jassat, Cheryl Cohen, Stefano Tempia, The Lancet HIV	2021	174
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial Florian von Groote-Bidlingmaier, R. F. Patientia, Epifanio Sánchez, The Lancet Respiratory Medicine	2019	161
Severe Influenza-associated Respiratory Infection in High HIV Prevalence Setting, South Africa, 2009–2011 Cheryl Cohen, Jocelyn Moyes, Stefano Tempia, Emerging infectious diseases Virus EpidemiologyFlu VaccinationClinical EpidemiologySouth AfricaRespiratory Infection	2013	154
Decline of influenza and respiratory syncytial virus detection in facility-based surveillance during the COVID-19 pandemic, South Africa, January to October 2020 Stefano Tempia, Sibongile Walaza, Jinal N. Bhiman, Eurosurveillance	2021	152
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial Conor Tweed, Rodney Dawson, Divan A. Burger, The Lancet Respiratory Medicine	2019	143
Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis Norbert Ndjeka, Francesca Conradie, Kathryn Schnippel, The International Journal of Tuberculosis and Lung Disease	2015	136

Page 1